Metraipolis › archive › dc_d2ca188aa98c
Post-marketing safety profile of palivizumab: a 20-year pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) — Europe PMC PMID:42240666
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42240666
- DOI
- 10.1007/s00210-[numero omesso]-5
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-31T19:19:25.351Z
- SHA-256 of the archived text
a20d940b8bcf116bf833b6f21514e6eb552491462325af243aaf793b3665fd31- Stable URL of this page
https://metraipolis.com/documento/dc_d2ca188aa98c
How to cite
Post-marketing safety profile of palivizumab: a 20-year pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) — Europe PMC PMID:42240666 — Europe PMC (en), https://europepmc.org/article/MED/42240666 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d2ca188aa98c (Metraipolis archive dc_d2ca188aa98c, sha256 a20d940b8bcf116bf833b6f21514e6eb552491462325af243aaf793b3665fd31)
BibTeX
@misc{dcd2ca188aa98c,
title = {Post-marketing safety profile of palivizumab: a 20-year pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) — Europe PMC PMID:42240666},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42240666},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d2ca188aa98c; sha256 a20d940b8bcf116bf833b6f21514e6eb552491462325af243aaf793b3665fd31},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42240666. Agents can read the archived copy with the MCP tool read_document.